Literature DB >> 20599790

Why we should be vigilant: drug cytotoxicity observed with in vitro transporter inhibition studies.

Xiaowan Zheng1, Lei Diao, Sean Ekins, James E Polli.   

Abstract

From routine in vitro drug-transporter inhibition assays, observed inhibition is typically assumed from direct interaction with the transporter. Other mechanisms that possibly reduce substrate uptake are not frequently fully examined. The objective of this study was to investigate the association of transporter inhibition with drug cytotoxicity. From a pool of drugs that were identified as known ASBT or OCTN2 inhibitors, 21 drugs were selected to screen inhibitory potency of their prototypical substrate and cytotoxicity against three human sodium-dependent solute carrier (SLC) transporters: apical sodium-dependent bile acid transporter (ASBT), organic cation/carnitine transporter (OCTN2), and the excitatory amino acid transporter 4 (EAAT4) in stable cell lines. Twenty drugs showed apparent inhibition in OCTN2-MDCK and ASBT-MDCK. Four dihydropyridine calcium channel blockers were cytotoxic to MDCK cells, and the observed cytotoxicity of three of them accounted for their apparent OCTN2 inhibition, and consequently were classified as non-OCTN2 inhibitors. Meanwhile, since their cytotoxicity only moderately contributed to ASBT inhibition, these three were still considered ASBT inhibitors. Four other drugs showed apparent inhibition in EAAT4-HEK cells, and cytotoxicity of three drugs corresponded with their inhibition of this transporter. Therefore, cytotoxicity significantly affected EAAT4 observations. Results showed the potential of cytotoxicity as a mechanism that can account for apparent in vitro transporter inhibition. Drug cytotoxicity varied in different cell lines, which could increase false positives for pharmacophore development. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20599790      PMCID: PMC2944038          DOI: 10.1016/j.bcp.2010.06.012

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  42 in total

1.  Inhibitory effects of statins on human monocarboxylate transporter 4.

Authors:  Masaki Kobayashi; Yukio Otsuka; Shirou Itagaki; Takeshi Hirano; Ken Iseki
Journal:  Int J Pharm       Date:  2006-04-18       Impact factor: 5.875

Review 2.  Pharmacophore-based discovery of ligands for drug transporters.

Authors:  Cheng Chang; Sean Ekins; Praveen Bahadduri; Peter W Swaan
Journal:  Adv Drug Deliv Rev       Date:  2006-09-26       Impact factor: 15.470

3.  Enhancement of chemical rules for predicting compound reactivity towards protein thiol groups.

Authors:  James T Metz; Jeffrey R Huth; Philip J Hajduk
Journal:  J Comput Aided Mol Des       Date:  2007-03-06       Impact factor: 3.686

Review 4.  Cytotoxic potential of phenothiazines.

Authors:  Noboru Motohashi; Masami Kawase; Kazue Satoh; Hiroshi Sakagami
Journal:  Curr Drug Targets       Date:  2006-09       Impact factor: 3.465

5.  Substrate specificity of the ileal and the hepatic Na(+)/bile acid cotransporters of the rabbit. II. A reliable 3D QSAR pharmacophore model for the ileal Na(+)/bile acid cotransporter.

Authors:  K H Baringhaus; H Matter; S Stengelin; W Kramer
Journal:  J Lipid Res       Date:  1999-12       Impact factor: 5.922

6.  Effects of new 4-aryl-1,4-dihydropyridines and 4-arylpyridines on drug efflux mediated by multidrug resistance-associated protein 1.

Authors:  Xiao-Fei Zhou; Robert A Coburn; Marilyn E Morris
Journal:  J Pharm Sci       Date:  2005-10       Impact factor: 3.534

7.  BCRP transports dipyridamole and is inhibited by calcium channel blockers.

Authors:  Yi Zhang; Anshul Gupta; Honggang Wang; Lin Zhou; R Robert Vethanayagam; Jashvant D Unadkat; Qingcheng Mao
Journal:  Pharm Res       Date:  2005-11-01       Impact factor: 4.200

8.  Inhibitory potencies of 1,4-dihydropyridine calcium antagonists to P-glycoprotein-mediated transport: comparison with the effects on CYP3A4.

Authors:  M Katoh; M Nakajima; H Yamazaki; T Yokoi
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

9.  The calcium channel blockers, 1,4-dihydropyridines, are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2.

Authors:  Suneet Shukla; Robert W Robey; Susan E Bates; Suresh V Ambudkar
Journal:  Biochemistry       Date:  2006-07-25       Impact factor: 3.162

10.  Development of stably transfected monolayer overexpressing the human apical sodium-dependent bile acid transporter (hASBT).

Authors:  Anand Balakrishnan; Daniel J Sussman; James E Polli
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

View more
  6 in total

1.  Making Transporter Models for Drug-Drug Interaction Prediction Mobile.

Authors:  Sean Ekins; Alex M Clark; Stephen H Wright
Journal:  Drug Metab Dispos       Date:  2015-07-21       Impact factor: 3.922

Review 2.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

3.  Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP).

Authors:  Zhongqi Dong; Sean Ekins; James E Polli
Journal:  Mol Pharm       Date:  2013-02-12       Impact factor: 4.939

Review 4.  The solute carrier family 10 (SLC10): beyond bile acid transport.

Authors:  Tatiana Claro da Silva; James E Polli; Peter W Swaan
Journal:  Mol Aspects Med       Date:  2013 Apr-Jun

5.  Long-chain acyl-CoA dehydrogenase deficiency as a cause of pulmonary surfactant dysfunction.

Authors:  Eric S Goetzman; John F Alcorn; Sivakama S Bharathi; Radha Uppala; Kevin J McHugh; Beata Kosmider; Rimei Chen; Yi Y Zuo; Megan E Beck; Richard W McKinney; Helen Skilling; Kristen R Suhrie; Anuradha Karunanidhi; Renita Yeasted; Chikara Otsubo; Bryon Ellis; Yulia Y Tyurina; Valerian E Kagan; Rama K Mallampalli; Jerry Vockley
Journal:  J Biol Chem       Date:  2014-03-03       Impact factor: 5.157

6.  Quantitative NTCP pharmacophore and lack of association between DILI and NTCP Inhibition.

Authors:  Zhongqi Dong; Sean Ekins; James E Polli
Journal:  Eur J Pharm Sci       Date:  2014-09-16       Impact factor: 4.384

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.